LISTING OF CLAIMS

1. *(previously presented):* A method for producing mononuclear cells overexpressing IL-10, comprising

(a) providing mammalian peripheral blood mononuclear cells wherein, if the cells comprise lymphocytes, the lymphocytes are not selected or enriched on the basis of their antigen specificity;

(b) introducing into at least a fraction of said mononuclear cells an expression construct that comprises a nucleotide sequence encoding an IL-10 polypeptide; and,

(c) recovering mononuclear cells that overexpress the polypeptide.

2. *(previously presented):* A method according to claim 1, wherein an enriched fraction or subset of said peripheral blood mononuclear cells are provided.

3. *(previously presented):* A method according to claim 2, wherein the enriched fraction is selected from the group consisting of lymphocytes or a subset thereof, macrophages, monocytes or dendritic cells (DC).

4. *(previously presented):* A method according to claim 1, wherein prior to step (b), the mononuclear cells are induced to, or allowed to, proliferate.

5. *(previously presented):* A method according to claim 4, wherein the mononuclear cells are induced to proliferate by a proliferating agent.

6. *(previously presented):* A method according to claim 5, wherein the proliferating agent is one or more of

(a) an anti-CD3 antibody;

(b) an anti-CD28 antibody; or

(c) phytohemagglutinin.

7. *(previously presented):* A method according to claim 1, wherein subsequent to step (b), the mononuclear cells are fractionated to yield an enriched a fraction or subset thereof.

8. *(previously presented):* A method according to claim 7, wherein the fraction or subset comprises enriched

(i) lymphocytes or a subset thereof,

(ii) macrophages or monocytes, or

(iii) dendritic cells.

9. *(previously presented):* A method according to claim 1, wherein subsequent to step (b), the mononuclear cells are enriched for cells that overexpress the nucleotide sequence.

10. *(previously presented):* A method for producing a pharmaceutical composition comprising mononuclear cells overexpressing IL-10, which method comprises combining

(a) the mononuclear cells overexpressing IL-10 produced in accordance with claim 1 with

(b) an acceptable pharmaceutical carrier.

10. ***(currently** amended):* A method for producing a pharmaceutical composition comprising mononuclear cells overexpressing IL-10, which method comprises ~~combining~~

(a) producing the mononuclear cells overexpressing IL-10 ~~produced~~ in accordance with claim 1, and

~~with~~

(b) combining said cells with an acceptable pharmaceutical carrier.

11. *(withdrawn):* A composition comprising mononuclear cells that comprise an IL-10 transgene.

12. *(withdrawn):* A composition according to claim 11, wherein the mononuclear cells comprise T cells that comprise said IL-10 transgene.

13. *(withdrawn):* A composition according to claim 12, wherein the T cells functionally mimic regulatory T cells in that they inhibit:

(a) proliferation of autologous responder cells, and/or

(b) production of pro-inflammatory cytokine IL-12 by dendritic cells.

14. *(withdrawn):* A pharmaceutical composition comprising the composition according to claim 11, and a pharmaceutically acceptable carrier.

15. *(withdrawn):* A method of treating a disease or condition associated with undesired activation and/or expansion of T cells, which method comprises administering an effective amount of a pharmaceutical composition according to claim 14 to a subject suffering from said disease or condition.

16. *(withdrawn):* A method according to claim 15, wherein the disease or condition is a Th1-mediated disease or condition.

17. *(withdrawn):* A method according to claim 16, wherein the Th1-mediated disease or condition is Crohn's disease, reactive arthritis, insulin-dependent diabetes, colitis, pancreatitis, an inflammatory lung disease, an inflammatory eye disease, multiple sclerosis, Hashimoto's thyroiditis, Graves' disease, chronic articular rheumatism, contact dermatitis, psoriasis, graft rejection, graft-versus-host disease, or sarcoidosis.

Claims 18 and 19 [previously canceled]

20. *(previously presented)* A method according to claim 3 wherein the lymphocyte subset comprises an enriched population of B cells, T cells or CD4+ cells.

21. *(previously presented)* A method according to claim 8 wherein the lymphocytes subset comprises an enriched population of B cells, T cells or CD4+ cells.

22. *(previously presented)* The method of claim 9 wherein said overexpressed nucleotide sequence encodes IL-10.

23. *(withdrawn)* A method according to claim 16 wherein the Th1-mediated disease is an inflammatory disease.